OUTLOOK THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.07 USD | -2.08% |
|
-10.51% | -10.28% |
| May. 28 | Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD | MT |
| May. 21 | CoStar Group has room for expansion |  |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 9.52M | Capitalization | 165M |
|---|---|---|---|---|---|
| Net income 2024 * | -121M | Net income 2025 * | -66M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 17.4 x |
| P/E ratio 2024 * |
-1.26
x | P/E ratio 2025 * |
-3.17
x | Employees | 24 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Outlook Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -2.08% | ||
| 1 week | -10.51% | ||
| 1 month | -20.74% | ||
| 3 months | -19.07% | ||
| 6 months | -26.35% | ||
| Current year | -10.28% |
1 week
6.89
7.95
1 month
6.808.91
Current year
5.0412.85
1 year
4.0040.60
3 years
4.0065.40
5 years
4.0085.20
10 years
4.00878.40
| Managers | Title | Age | Since |
|---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 1,487 M€ | +7.77% | - | |
| 0.00% | 9 M€ | +9.86% | - | |
| 0.00% | 17 M€ | +4.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 7.07 | -2.08% | 166,606 |
| 24-05-30 | 7.22 | +1.26% | 233,461 |
| 24-05-29 | 7.13 | -10.14% | 256,835 |
| 24-05-28 | 7.935 | +0.44% | 661,628 |
| 24-05-24 | 7.9 | +4.91% | 228,601 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Calendar
2024-08-13
- Q3 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.07
USD
Average target price
38.43
USD
Spread / Average Target
+443.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.28% | 165M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- OTLK Stock
